First, according to published results which will be detailed later, GIST patients with PDGFRA D842V mutation, KIT-WT genotype, TLS presence or high PD-L1 expression seemed to have more probabilities to benefit from ICIs and should be selected preferentially [153, 189]. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.